Results 151 to 160 of about 233,161 (342)

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
David Kudrow   +3 more
wiley   +1 more source

Hairy Leukoplakia [PDF]

open access: yes, 2017
Oral hairy leukoplakia (OHL) is a disease of the mucosa first described in 1984. This pathology is associated with Epstein-Barr virus (EBV) and occurs mostly in people with HIV infection, both immunocompromised and immunocompetent, and can affect ...
Agarwala, Sanjiv S.   +5 more
core   +1 more source

Epstein-Barr Virus Gastritis

open access: yesInternal Medicine, 2017
Masayuki, Oki   +2 more
openaire   +3 more sources

Making sense of TILs: recommendations for morphological assessment of tumour‐infiltrating lymphocytes in gastro‐oesophageal carcinoma

open access: yesHistopathology, EarlyView.
This review examines the role of tumour‐infiltrating lymphocytes (TILs) in gastro‐oesophageal carcinoma (GEC), focusing on their composition, clinical relevance and therapeutic utility. It proposes a framework for standardised evaluation and reporting of TILs, addressing GEC‐specific pathology challenges to support the widespread use and validation of ...
Ylva A Weeda   +38 more
wiley   +1 more source

Immune non‐response despite effective antiretroviral therapy in people living with HIV: A review of potential mechanisms, biomarkers and therapeutic approaches

open access: yesHIV Medicine, EarlyView.
Abstract Introduction A proportion of people living with HIV (PLWH) fail to restore their CD4 count or their CD4/CD8 ratio despite effective antiretroviral therapy (ART). PLWH with immune non‐response (INR) are at a higher risk of both AIDS and non‐AIDS events. The underlying mechanisms of INR remain unclear.
Charlotte Silvestre   +2 more
wiley   +1 more source

Pembrolizumab as salvage treatment for T‐cell/histiocyte‐rich and Epstein–Barr virus‐positive large B‐cell lymphoma [PDF]

open access: bronze
Alberto Schena   +7 more
openalex   +1 more source

Serodiagnosis of infectious mononucleosis by using recombinant Epstein-Barr virus antigens and enzyme-linked immunosorbent assay technology [PDF]

open access: yes, 1990
Four recombinant, diagnostically useful Epstein-Barr virus (EBV) proteins representative of the viral capsid antigen (p150), diffuse early antigen (p54), the major DNA-binding protein (p138), and the EBV nuclear antigen (p72) (W. Hinderer, H.
Gorgievski-Hrisoho, M.   +7 more
core   +1 more source

Immune‐related toxicity profile after haematopoietic stem cell transplantation in patients with B‐ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab

open access: yes
British Journal of Haematology, EarlyView.
Olayinka Okeleji   +7 more
wiley   +1 more source

Mycobacterium avium Subsp. paratuberculosis and Human Endogenous Retrovirus in Italian Patients With Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS)

open access: yesImmunology, EarlyView.
Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn's disease (CD), is a recognised gastrointestinal disorder. Mycobacterium avium subspecies paratuberculosis (MAP) is implicated in IBD pathogenesis. Persistent exposure and active infections by MAP may contribute to the unsilencing of human endogenous retroviruses (HERV ...
Stefano Ruberto   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy